Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas

Zou,Yang; Huang,Mei‑Zhen; Liu,Fa‑Ying; Yang,Bi‑Cheng; Wang,Li‑Qun; Wang,Feng; Yu,Xiao‑Hong; Wan,Lei; Wan,Xi‑Di; Xu,Xiao‑Yun; Li,Wei; Huang,Ou‑Ping; He,Ming

doi:10.3892/br.2014.378

Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas

Authors:
- Yang Zou
- Mei‑Zhen Huang
- Fa‑Ying Liu
- Bi‑Cheng Yang
- Li‑Qun Wang
- Feng Wang
- Xiao‑Hong Yu
- Lei Wan
- Xi‑Di Wan
- Xiao‑Yun Xu
- Wei Li
- Ou‑Ping Huang
- Ming He
View Affiliations

Affiliations: Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Pathology, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Pharmacology and Molecular Therapeutics, Nanchang University School of Pharmaceutical Science, Nanchang, Jiangxi 330006, P.R. China
Published online on: November 7, 2014 https://doi.org/10.3892/br.2014.378
Pages: 33-37

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is caused by multiple genetic alterations within cells. Recently, large‑scale sequencing has identified frequent ribonuclease type III (DICER1), CCCTC‑binding factor (CTCF), ribosomal protein L22 (RPL22), DNA (cytosine‑5‑)‑methyltransferase 3α (DNMT3A), transformation/transcription domain‑associated protein (TRRAP), isocitrate dehydrogenase (IDH)1 and IDH2 hotspot mutations in diverse types of cancer. However, it remains largely unknown whether these mutations also exist in ovarian carcinomas. In the present study, a collection of 251 patients with distinct subtypes of ovarian carcinomas were recruited and sequenced for the presence of these hotspot mutations. However, no mutations in the seven genes were detected in the samples. These negative results, together with certain recent reports, indicate that the hotspot mutations in the CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 genes may not be actively involved in the carcinogenesis of ovarian carcinoma. Of note, the DICER1 mutation frequency in Sertoli‑Leydig cell tumor in the present study was significantly lower compared to prior observation, and therefore, it is speculated that this discrepancy may be mainly due to the small sample size analyzed in the study. In addition, among these samples, frequent polymerase (DNA directed) ε, catalytic subunit (POLE1) and ring finger protein 43 (RNF43) mutations were identified in endometrioid and mucinous ovarian carcinomas, respectively; thus DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations may not play synergistic roles with POLE1 or RNF43 mutations in the carcinogenesis of endometrioid or mucinous ovarian carcinomas.

View Figures

View References

1	Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wu J, Jiao Y, Dal Molin M, et al: Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 108:21188–21193. 2011. View Article : Google Scholar : PubMed/NCBI
3	Heravi-Moussavi A, Anglesio MS, Cheng SW, et al: Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 366:234–242. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 363:2424–2433. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tefferi A, Lasho TL, Abdel-Wahab O, et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 24:1302–1309. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ogino S, Liao X, Imamura Y, et al: Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 105:1789–1798. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar
9	Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
10	Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rafnar T, Gudbjartsson DF, Sulem P, et al: Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 43:1104–1107. 2011. View Article : Google Scholar : PubMed/NCBI
12	Loveday C, Turnbull C, Ramsay E, et al: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 43:879–882. 2011. View Article : Google Scholar : PubMed/NCBI
13	Jones S, Wang TL, Shih IeM, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
14	Romero I, Sun CC, Wong KK, Bast RC Jr and Gershenson DM: Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 130:660–666. 2013. View Article : Google Scholar : PubMed/NCBI
15	Martini M, Vecchione L, Siena S, Tejpar S and Bardelli A: Targeted therapies: how personal should we go? Nat Rev Clin Oncol. 9:87–97. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yoshida K, Toki T, Okuno Y, et al: The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 45:1293–1299. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zighelboim I, Mutch DG, Knapp A, et al: High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers. Hum Mutat. 35:63–65. 2014. View Article : Google Scholar : PubMed/NCBI
18	Novetsky AP, Zighelboim I, Thompson DM Jr, Powell MA, Mutch DG and Goodfellow PJ: Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol. 128:470–474. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 43:442–446. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
21	Abbas S, Lugthart S, Kavelaars FG, et al: Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 116:2122–2126. 2010. View Article : Google Scholar : PubMed/NCBI
22	Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI
23	Im AP, Sehgal AR, Carroll MP, et al: DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 28:1774–1783. 2014. View Article : Google Scholar
24	Kihara R, Nagata Y, Kiyoi H, et al: Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 28:1586–1595. 2014. View Article : Google Scholar
25	Zou Y, Wang F, Liu FY, et al: RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer. Gene. 531:112–116. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zou Y, Liu FY, Liu H, et al: Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat Res Fundam Mol Mech Mutagen. 761:49–52. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF and Yao YG: IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun. 402:378–383. 2010. View Article : Google Scholar : PubMed/NCBI
28	Witkowski L, Mattina J, Schonberger S, et al: DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer. 109:2744–2750. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ryland GL, Hunter SM, Doyle MA, et al: RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol. 229:469–476. 2013. View Article : Google Scholar : PubMed/NCBI
30	Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
31	Murugan AK, Yang C and Xing M: Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncol Lett. 6:437–441. 2013.PubMed/NCBI
32	Parry M, Rose-Zerilli MJ, Gibson J, et al: Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 8:e832442013. View Article : Google Scholar : PubMed/NCBI
33	Yan XJ, Xu J, Gu ZH, et al: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 43:309–315. 2011. View Article : Google Scholar : PubMed/NCBI
34	Neumann M, Heesch S, Schlee C, et al: Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 121:4749–4752. 2013. View Article : Google Scholar : PubMed/NCBI
35	Walter MJ, Ding L, Shen D, et al: Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 25:1153–1158. 2011. View Article : Google Scholar : PubMed/NCBI
36	Kim MS, Kim YR, Yoo NJ and Lee SH: Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers. APMIS. 121:85–94. 2013. View Article : Google Scholar : PubMed/NCBI
37	Bleeker FE, Lamba S, Leenstra S, et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 30:7–11. 2009. View Article : Google Scholar : PubMed/NCBI
38	Kang MR, Kim MS, Oh JE, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 125:353–355. 2009. View Article : Google Scholar : PubMed/NCBI
39	Mauzo SH, Lee M, Petros J, et al: Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas. Appl Immunohistochem Mol Morphol. 22:284–287. 2014. View Article : Google Scholar : PubMed/NCBI